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Abstract
Background and Objectives: Human papillomaviruses have been linked causally to some human cancers such as cervical
carcinoma, but there is very little research addressing the effect of HPV infection on human liver cells. We chose the human
hepatoma derived cell line Hep G2 to investigate whether HPV gene integration took place in liver cells as well.
Methods: We applied PCR to detect the possible integration of HPV genes in Hep G2 cells. We also investigated the
expression of the integrated E6 and E7 genes by using RT-PCR and Western blotting. Then, we silenced E6 and E7
expression and checked the cell proliferation and apoptosis in Hep G2 cells. Furthermore, we analyzed the potential genes
involved in cell cycle and apoptosis regulatory pathways. Finally, we used in situ hybridization to detect HPV 16/18 in
hepatocellular carcinoma samples.
Results: Hep G2 cell line contains integrated HPV 18 DNA, leading to the expression of the E6 and E7 oncogenic proteins.
Knockdown of the E7 and E6 genes expression reduced cell proliferation, caused the cell cycle arrest at the S phase, and
increased apoptosis. The human cell cycle and apoptosis real-time PCR arrays analysis demonstrated E6 and E7-mediated
regulation of some genes such as Cyclin H, UBA1, E2F4, p53, p107, FASLG, NOL3 and CASP14. HPV16/18 was found in only
9% (9/100) of patients with hepatocellular carcinoma.
Conclusion: Our investigations showed that HPV 18 E6 and E7 genes can be integrated into the Hep G2, and we observed
a low prevalence of HPV 16/18 in hepatocellular carcinoma samples. However, the precise risk of HPV as causative agent of
hepatocellular carcinoma needs further study.
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Introduction
Epidemiological studies have shown that HPV infection is the
main etiological factor for cervical cancer [1] and high-risk HPV
type viral DNAs are frequently integrated into the host cell
genome in HPV-related cervical carcinomas [2]. This integration
has been associated with dysregulation of E6 and E7 viral genes
expression, which accounts for the major oncogenic activity of the
HPV DNA [3]. Expression of these genes can lead to immortal-
ization of keratinocytes, the natural host cells of HPV [4].
However, little information is available about the integration of
HPV into human liver cells.
The human hepatoma derived cell line Hep G2 was derived
from biopsies taken during extended lobectomy of a 15-year-old
Caucasian male from Argentina [5]. This cell line has been used in
many laboratories around the world and we discovered that the
Hep G2 cell line contained the integrated DNA of HPV 18. All the
HPV viruses live exclusively in the superficial tissues that cover our
body parts: the skin, the lining of the genital organs, urethra,
bladder, rectum, vocal cords, and esophagus. It remains unclear
whether there is an association between HPV infection and
hepatocellular carcinoma. Our interest in such a putative associ-
ation was the impetus that led us to investigate the expression of
E6 and E7 oncogenes in the Hep G2 cell line, and furthermore, to
see if such expression is required for the maintenance of the
proliferative and malignant phenotypes of Hep G2 cell line.
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Immunohistochemistry revealed that the Hep G2 cell line
was typical of liver cells
In order to characterize the Hep G2 cell line more explicitly, we
used the anti-human hepatocyte antibody to verify the character-
istics of the hepatoma cells. Anti-human hepatocyte immunohis-
tochemical evaluation of Hep G2 with the hepatocyte-specific
marker confirmed that the Hep G2 cell line was positive in liver
cell antigens (Fig. 1A), but the HeLa cells were negative (Fig. 1B).
Hep G2 cells with integrated HPV 18 DNA expressed E6
and E7 mRNAs and proteins
An amplified fragment of 847 bp was present in both the Hep
G2 and EC109 cells (HPV 18 positive) while it was absent in K562
cells (HPV 18 negative), as was expected (Fig. 2A).
Transcription of the HPV 18 E6 and E7 genes in the Hep G2
and EC109 cell lines were evaluated by RT-PCR. The results
showed that the expected fragments of E6 (196 bp) and E7
(332 bp) were present in both Hep G2 and EC109 cells, but not in
K562 cells (Fig. 2B). Western blot analysis of cell extracts was also
carried out to determine whether mRNA expression was
correlated with translation of the gene products. Again, a specific
protein band (18 kD) of E6 and E7 was observed in both Hep G2
and EC109 cells, but not in K562 cells (Fig. 2C). b-actin was used
as an internal control.
Inhibition of both E6 and E7 genes expression by HPV 18
E7 siRNA
We designed three siRNAs targeting E7 gene and screened for
more effective siRNAs using RT-PCR assay. We found that two of
three siRNAs (siRNA E7-63 and siRNA E7-112) were more
effective (Fig. 3A). The level of E7 mRNA in Hep G2 cells
transfected with siRNA E7-63 and E7-112 decreased to
14.51%62.06% and 35.89%61.00% respectively compared with
that of the NC E7 (negative control) transfected cells. The level of
E6 mRNA in Hep G2 cells transfected with siRNA E7-63 and E7-
112 decreased to 36.50%610.12% and 24.50%67.32% re-
spectively compared with that of the NC E7 (negative control)
transfected cells (p,0.01, Fig. 3B). To overcome limitations of
RNAi experiments, such as off-target effects, we mixed siRNA E7-
63 and E7-112 to obtain our siRNA pools. The expression of E7
and E6 at mRNA and protein levels was assessed at different times
after transfection. There were significant decreases in E6 and E7
mRNA levels at 24 and 48 hours after siRNA treatment when
compared with that of control siRNA treated cells (Fig. 3C). At
24 h and 48 h after transfections, the level of E7 mRNA in Hep
G2 cells transfected with siRNA E7 pools decreased to
57.93%60.31% and 8.79%60.42% respectively compared with
that of the NC E7 transfected cells. At 24 h and 48 h after
transfections, the level of E6 mRNA in Hep G2 cells transfected
with siRNA E7 pools decreased to 68.14%60.53% and
0.63%60.02% respectively compared with that of the NC E7
transfected cells (p,0.01, Fig. 3D).
Knockdown of HPV 18 E7 and E6 genes inhibited cell
growth
To determine whether the inhibition of HPV 18 E7 and E6
genes was sufficient to suppress the proliferation of Hep G2 cells,
cells were assessed using EdU assays for analyzing the S-phase
fraction (SPF). After transfections of Hep G2 cells with E7-siRNA,
a time-dependent reduction of cell S-phase fraction was observed
at 48 h, 60 h and 72 h (Fig. 4A). At 48 h, 60 h and 72 h following
E7-siRNA transfections, the percents of S-phase cells were
9.39%63.55%, 17.29%65.85% and 30.87%64.26% compared
with 18.74%66.66%, 24.03%65.35% and 41.97%68.73% in
NC-siRNA transfected cells (P,0.05, Fig. 4B).
Transfection with E7-siRNA induced apoptosis
To assess the ratio of cell death, the Annexin V apoptosis assay
was performed at 24 h, 48 h and 72 h after siRNA transfections
and the stained cells were analyzed by flow cytometry in the
experimental and negative control groups. As shown in Fig. 5A, B,
C and D, 7.26%60.29%, 22.03%60.23% and 19.20%60.78%
in siRNA E7-transfected Hep G2 cells after 24 h, 48 h and 72 h
underwent total apoptosis compared with only 5.25%60.76% in
NC-E7 transfected cells. The fourth and first quadrant cells were
counted and expressed as the percentages of apoptotic cells.
Therefore, knockdown of E7 resulted in about a 4-fold increase in
apoptosis (P,0.01, Fig. 5E).
Real-time PCR array analysis of shRNA E7 induced
apoptosis and cell cycle gene transcriptional profiles
In this study, we compared the gene expression patterns of cell
cycle and apoptosis signaling pathways in Hep G2 cells transfected
with shRNA E7 or negative control shRNA at 48 h after
transfections. A total of 40 out of 168 genes in PCR Array
showed differential expressions when cells transfected with shRNA
E7 and NC-shRNA were compared. Data analysis indicated that
among the cell cycle PCR array, 7 genes were up-regulated and 12
Figure 1. Immunohistochemistry demonstrated that the Hep G2 cell line was of characteristics typical of liver cells.
Immunohistochemical evaluation of Hep G2 cells with anti-human hepatocyte antibody indicated that the Hep G2 cell cytoplasm (A), but not
HeLa cells (B), exhibited typical hepatocyte antigens.
doi:10.1371/journal.pone.0037964.g001
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Cyclin H, CDK2, E2F4, p53, Cullin3, MKI67, UBA1, p107 and
others were affected. After the knockdown of E7, in Apoptosis
PCR Array, 16 genes were up-regulated and 5 genes were down-
regulated. Affected genes were BAK1, BCL2L10, CARD8,
CASP2, CASP8, CASP14, FASLG, NOL3, CD27 and other
genes (Table 2).
In situ hybridization on tissue microarrays for HPV 16/18
The HPV signals observed in the punctate nuclear staining of
Hep G2 cells (Fig. 6A) and HeLa cells (positive control)
demonstrated an integrated form of HPV DNA (Fig. 6B). HPV
signals in the HPV-ISH-positive case were of diffuse staining in
tumor cells (Fig. 6C). No signal was found in hepatoma carcinoma
Figure 2. Hep G2 cells with integrated HPV 18 DNA expressed E6 and E7 mRNAs and proteins. (A) PCR amplification of HPV 18 E6E7 gene
was assessed in samples from Hep G2, EC109, and K562 cells. Then an amplified fragment of 847 bp was present in both Hep G2 and EC109 cells (HPV
18 positive), but absent in K562 cells (HPV 18 negative). (B) The expression of HPV 18 E6 and E7 mRNA was detected by RT-PCR. The expected
fragments of E6 (196 bp) and E7 (332 bp) were present in both Hep G2 and EC109 cells, but not in K562 cells. (C) Western blotting showed the
expression of the HPV 18 E6 and E7 proteins. EC109 and K562 were used as controls. b-actin was used as an internal control.
doi:10.1371/journal.pone.0037964.g002
Figure 3. HPV18 E6 and E7 mRNA and relative protein expressions in Hep G2 transfected with E7-siRNA. (A) Effective siRNAs were
screened using RT-PCR assays from three siRNAs targeting the E7 gene and two of three siRNAs (siRNA E7-63 and siRNA E7-63 112) were more
effective. (B) The level of E7 mRNA in Hep G2 cells transfected with siRNA E7-63 and siRNA E7-112 decreased to 14.51%62.06% and 35.89%61.00%
respectively compared with that of the NC siRNA E7 (Negative control) transfected cells (p,0.01). (C) The expression of E7 and E6 mRNA was assessed
through RT-PCR at different time after transfection. (D) At 24 h and 48 h after transfection, the level of E7 mRNA in Hep G2 cells transfected with
siRNA E7 decreased to 57.93%60.31% and 8.79%60.42% respectively compared with that of the NC siRNA E7 transfected cells (p,0.01).
doi:10.1371/journal.pone.0037964.g003
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tumor grade, HPV16/18 was positive in 2 of 28 patients (7.1%)
with grade I carcinoma, in 6 of 65 patients (8.8%) with grade II
carcinoma, and in 1 of 7 patients (14.2%) with grade III carcinoma
(Table 3). There was no association between carcinoma grade and
HPV infection (P=0.719).
Discussion
Chronic viral and bacterial infections and nematode infestations
have been estimated to be associated with approximately one out
of five human cancers worldwide [6]. The HPV genome has been
detected in esophagus, lung, colon, ovary, breast, and prostate.
However, there is little research addressing the ability of HPV to
infect hepatic cells and the effect it would have upon these cells.
Scinicariello F. et al detected human papillomavirus 16 and 18 in
primary hepatocellular carcinoma and found that tumors in 1 of
16 samples showed HPV 16 positive and 2 of 16 samples showed
HPV 18 positive [7].HPV is a simple DNA virus that has evolved
to escape immune attack by a combination of stealth and
interference. HPV life cycle has rare by-products to trigger
immune response and E6E7 oncoproteins also target cytokine
expression to modulate cell proliferation and interferon responses,
contributing to immune evasion [8]. When the immune system is
weakened, HPV is likely carried to the liver of the patients from
a distant site via blood circulation. This may explain why HPV
viremia occurs more frequently than previously believed.
Our research have shown that the hepatoma derived cell line
Hep G2 was positive for HPV 18 and this infection led to the
integration of viral DNA into the host genome and expression of
the E6 and E7 oncogenes. For a long time, there has been
controversies about the precise origin of Hep G2 cell line. The
HeLa cells do contaminate a number of established cell lines. A
major issue here was to determine if this line was a cervical
adenocarcinoma, a carcinoma of the cervix metastatic to the liver,
a primary hepatoma cell line, or a contaminated pailloma positive
HeLa cell line. Anti-hepatocyte immunohistochemistry convinc-
ingly demonstrated that Hep G2 cell line was of typical
characteristics of liver cells. This evidence suggested a possible
association between HPV 18 infection and hepatocellular carci-
noma (HCC). As a basic biological characteristic, HPV virus
causes proliferation of infected host cells. This is often manifested
clinically in skin or mucous membrane warts. It is unknown
whether HPV plays a role in HCC carcinogenesis, or whether
HPV and HBV co-infection may have a synergistic effect. Lee et al
found that HPV 16 E6 oncoprotein and HBV X protein could
synergistically induce the activation of the AP1 site of E element in
the enhancer I (EnI) to increase the transcription activity of the
HBV and other oncogenes containing an AP1 site in the promoter
in human liver cell [9]. Both HBV and HPV are DNA viruses, and
share, along with oncogenic retroviruses, a replication strategy
involving reverse transcriptase and a characteristic life cycle that
includes integration of viral DNA into the host genome [10]. Viral
integration into or adjacent to the human telomerase reverse
transcriptase (hTERT) gene, for example, may lead to hTERT
telomerase activation, cellular immortalization, and a predisposi-
tion to carcinogenesis in liver and cervical cancers [11]. The HPV
oncoproteins E6 and E7 are the primary viral factors responsible
for initiation and progression of cancer. A primary target of E7 is
the retinoblastoma (Rb) family of proteins that control the activity
of E2F transcription factors, which are key regulators of S phase
genes. Inactivation of Rb is important for the differentiation-
dependent productive viral lifecycle and for tumor progression.Th-
ese high-risk E6 and E7 oncoproteins then lead to cell proliferation
through their association with PDZ domain proteins and, through
p53 degradation, prevent the normal repair of chance mutations
in the cellular genome [12]. E7 oncoprotein also alters cell cycle
control through interactions with histone deacetylases, cyclins and
cyclin-dependent kinase inhibitors. These factors are crucial
regulators of immune evasion, cell cycle progression, telomere
maintenance, apoptosis and chromosomal stability. HPV onco-
proteins modify these activities to play an important role in the
basic mechanisms of oncogenesis [13,14]
In recent years, most researchers have reported that down-
regulation of HPV18 E6 and E7 expression by RNAi led to
retarded growth of HPV18-positive cervical cancer cell lines [15]
and proposed that siRNA-induced E6 and E7 simultaneously
silencing had a major therapeutic potential. When we silenced the
E7 and E6 by RNAi, Hep G2 cells in the S-phase reduced and
apoptosis increased. We found that silencing HPV E7 and E6
could affect the expression of genes involved in cell-cycle
regulation, such as Cyclin H, CDK2, E2F4, p53, Cullin3,
MKI67, UBA1, p107 and so on. In our study, the knockdown
of HPV E7 could affect the genes of cell apoptosis including
BAK1, BCL2L10, CARD8, CASP2, CASP8, CASP14, FASLG,
NOL3 and CD27. Therefore, integration of the HPV E7 and E6
genes into Hep G2 cells may play an important role in the
immortalization and carcinogenesis of this hepatoma cell line.
Figure 4. Inhibition of HPV 18 E7 gene inhibited cell growth in Hep G2. (A) Hep G2 cells transfected with E7-siRNA or control siRNA were
evaluated in EdU assays at 0 h, 12 h, 24 h, 36 h, 48 h, 60 h and 72 h after transfection. After transfection of Hep G2 cells with E7-siRNA, a time-
dependent reduction of cell proliferation was observed at 48 h, 60 h and 72 h. (B) At 48 h, 60 h and 72 h following E7-siRNA transfection, the
percents of S-phase cells were 9.39%63.55%, 17.29%65.85% and 30.87%64.26% compared with 18.74%66.66%, 24.03%65.35% and
41.97%68.73% in NC-siRNA transfected cells (p,0.05).
doi:10.1371/journal.pone.0037964.g004
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professionals to consider the effect that HPV infection has on
the development, investigation, and treatment of HCC. It is
standard practice to inoculate for HBV to prevent the de-
velopment of chronic HBV infection and HCC. Perhaps
consideration should also be given to the administration of HPV
vaccine in adult immunization, or to include HPV testing as part
of routine outpatient care. Patients with HCC who are HBV
positive undergo liver transplantation require antiviral therapy.
There is a benefit from viral suppression in the form of reducing
HBV recurrence after transplantation [16]. HPV status, on the
other hand, has never played a role in the consideration of liver
resection versus transplantation in patients with HCC. Perhaps
this stance should be investigated further.
In conclusion, our research showed that HPV 18 E6 and E7
genes can be integrated into the hepatoma cell line Hep G2,
leading to the expression of the E6 and E7 oncogenic proteins.
Furthermore our results demonstrated that RNAi inhibited the
expression of E7 as well as E6, and down-regulation of these viral
oncogenes initiated the process of growth arrest and induced
apoptosis in Hep G2 cells. Although 100 tumor samples were
analyzed and only 9% of cases tested positive for HPV 16/18 in
hepatocellular carcinoma, further research on the carcinogenic
potential of HPV infection in hepatic cells is warranted.
Materials and Methods
Cell lines and cell culture
The human hepatoma derived cell line Hep G2 [5] and human
esophageal carcinoma cell line EC109 cell lines were obtained
from the Committee of Type Culture Collection of the Chinese
Academy of Sciences (Shanghai, China). The human erythroleu-
Figure 5. Transfection with E7-siRNA induced apoptosis. (A, B, C and D) The percent of apoptotic Hep G2 cells was measured using the
Annexin V assay at 24 h, 48 h and 72 h after transfection, and then the stained cells were analyzed through flow cytometry. (E) The results showed
that 7.26%60.29%, 22.03%60.23% and 19.20%60.78% in siRNA E7 transfected Hep G2 cells after 24 h, 48 h and 72 h underwent total apoptosis
compared with only 5.25%60.76% in NC siRNA E7 transfected cells (p,0.05).
doi:10.1371/journal.pone.0037964.g005
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HeLa [18] were obtained from the Center for Molecular Biology
of Shantou University Medical College (Shantou, China). The cell
lines were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS)
(Invitrogen Gibco, USA) and grown at 37uC in a humidified
atmosphere with 5% CO2.
Immunohistochemistry for characterizing Hep G2 cells
Cells grown on slides were fixed in paraformaldehyde for
15 min and penetrated in Phosphate buffered saline (PBS)
containing 0.3% Triton X-100 for 30 min, then followed by
incubation with 3% hydrogen peroxide for 25 min. Washed in
PBS, slides were incubated with 1.5% normal horse serum in PBS
for 30 min with the purpose of blocking nonspecific binding. After
being rinsed in PBS for three times, slides were incubated
overnight at 4uC with mouse anti-human hepatocyte antibody
(1:100 dilution) (Invitrogen, USA). Slides were then incubated for
30 min with biotinylated anti-mouse antibody (1:200 dilution)
(VECTOR Lab, USA) followed by 30 min in Avidin: Biotinylated
Enzyme Complex at room temperature. Subsequently the
antibody-antigen binding sites were identified by applying sub-
strate diaminobenzidine. Finally, slides were dehydrated, and
mounted. HeLa cells were served as controls.
Polymerase chain reactions (PCR)
PCR amplification of HPV 18 E6 and E7 genes was performed
using Pfu DNA polymerase (Generay, Shanghai, China) and the
following HPV 18 E6 and E7 primers (forward 59GACACTAG-
TACTATGGCGCGCTTTGA39 and reverse 59AGTAC-
TAGTTTACAACCCGTGCCCTCC39). An initial denaturation
of 5 min at 94uC was followed by 30 cycles of amplification (30 s
at 94uC, 30 s at 62uC and 90 s at 72uC), with a final extension of
10 min at 72uC. The products of this PCR assay were sequenced
using bi-directional sequencing on an Applied Biosystems 3700
automated DNA sequencing machine in the GeneCore Bio-
technologies.
Reverse transcription PCRs (RT-PCR)
The total RNA of cells was extracted using Trizol reagent
according to the manufacturer’s protocol (TaKaRa, Japan).
Complementary DNA (cDNA) of cells was synthesized from
1 mg of total RNA using the ImProm-II
TM Reverse Transcription
System (Promega, USA). PCR was performed using Pfu DNA
polymerase and the following primers for HPV 18 E6 (forward:
59AAGATTTATTTGTGGTGT 39, reverse: 59GCTGGATT-
CAACGGTTTC 39) and for HPV 18 E7 (forward: 59TATG-
CATGGACCTAAGGC 39, reverse: 59CAGCCATTGTTGCT-
TACT 39). An initial denaturation of 5 min at 94uC was followed
by 30 cycles of amplification (30 s at 94uC, 30 s at 57uC and 30 s
at 72uC), with a final extension of 10 min at 72uC.
Western blot analysis
Protein samples from the cells were extracted with the
ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem,
USA) according to the manufacturer’s instructions. The protein
samples were boiled for 5 min in 16SDS sample buffer, and 50 mg
of the proteins were loaded in wells of a 15% sodium dodecyl
sulfate-polyacrylamide electrophoresis (SDS-PAGE) gel. Following
separation, the proteins were transferred to a nitrocellulose
Table 1. mRNA expression of E7-related genes in Hep G2 cells after the silencing of HPV 18 E7 through RT
2 Profiler
TM Human Cell
Cycle PCR Array.
Gene names Genbank accession no. Description Folds up- or down-regulation
ABL1 NM_005157 C-abl oncogene 1, receptor tyrosine kinase 22.20
ANAPC4 NM_013367 Anaphase promoting complex subunit 4 22.13
ATR NM_001184 Ataxia telangiectasia and Rad3 related 22.31
CCNH NM_001239 Cyclin H 22.80
CDK2 NM_001798 Cyclin-dependent kinase 2 2.12
CDKN2B NM_004936 Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 2.01
CKS1B NM_001826 CDC28 protein kinase regulatory subunit 1B 22.09
CUL3 NM_003590 Cullin 3 22.83
E2F4 NM_001950 E2F transcription factor 4, p107/p130-binding 3.27
MKI67 NM_002417 Antigen identified by monoclonal antibody Ki-67 22.48
MNAT1 NM_002431 Menage a trois homolog 1, cyclin H assembly factor
(Xenopus laevis)
2.04
NBN NM_002485 Nibrin 22.04
PCNA NM_182649 Proliferating cell nuclear antigen 22.08
RAD1 NM_002853 RAD1 homolog (S. pombe) 22.29
RBL1 NM_002895 Retinoblastoma-like 1 (p107) 2.83
RPA3 NM_002947 Replication protein A3, 14 kDa 22.08
SERTAD1 NM_013376 SERTA domain containing 1 22.20
TP53 NM_000546 Tumor protein p53 3.20
UBA1 NM_003334 Ubiquitin-like modifier activating enzyme 1 2.44
In 84 E7-related genes, 19 genes mRNA transcript were altered markedly compared with the negative control. Standards of eligibility: folds up- or down-regulation .2.0
and p,0.05; n=3.
doi:10.1371/journal.pone.0037964.t001
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temperature, the membrane was incubated overnight at 4uC with
primary antibodies specific for HPV 18 E6, HPV 18 E7 (Santa
Cruz, USA) and b-actin (Cell Signaling Technology, USA). The
immunoblot analysis was performed via enhanced chemilumines-
cence.
RNA interference
Synthetic target HPV 18 E7 siRNAs sequences (Table 4) were
obtained from GenePharma (Shanghai, China). The siRNA was
separately cloned into pGPH1 vector and this was verified through
DNA sequencing analysis performed at Shanghai GenePharma
Company. In brief, 5610
5 Hep G2 cells were cultured in 6-well
plates using 2 mL of DMEM supplemented with 10% FBS. After
incubation for 24 h when cells were about 50% confluent, they
were transfected with 2.16 mg of the siRNA-E7 pools (HPV 18 E7-
63, HPV 18 E7-112=1:1) or NC-E7 (Negative control), using
Lipofectamine
TM 2000 (Invitrogen, USA) transfection reagent at
a siRNA: Lipofectamine
TM 2000 ratio of 1.08 mg: 2 mL according
to the manufacturer’s instructions. Transfection was terminated
4,6 h later by replacing the medium with 2.0 mL fresh medium
containing 10% FBS.
EdU staining for cell proliferation
EdU is a novel alternative for BrdU assays to directly measure
active DNA synthesis or the S-phase DNA synthesis of the cell
cycle. At 0 h, 12 h, 24 h, 36 h, 48 h, 60 h, and 72 h after
transfection, cells transfected with siRNA-E7 or NC-E7 were
incubated with 50 mM EdU for two hours at 37uC using the Click-
iTH EdU Alexa FluorH 594 Imaging Kit (Invitrogen, USA)
according to the manufacturer’s instructions. After fixation, cells
were treated with the reagent containing Alexa 594 azide, followed
by the counterstaining with Hoechst 33342 for detection and
imaging using fluorescence microscopy.
Annexin V-FITC apoptosis assays
Apoptosis of Hep G2 cells were determined using the Annexin
V-FITC Apoptosis Detection Kit (Calbiochem, USA) according to
the manufacturer’s protocol. In brief, at 24 h, 48 h and 72 h after
being transfected with siRNA-E7 or NC-E7, cells were washed
twice in cold PBS and then resuspended in 16binding buffer at
a concentration of 1610
6 cells/mL. An aliquot of 500 ml solution
(5610
5 cells) was then transferred to another tube containing
1.25 mL Annexin V-FITC and the cells were gently vortexed and
incubated for 15 min at room temperature in the dark. Then an
aliquot of 500 mL cold 16binding buffer and 10 mL PI were added
and the cells were analyzed with a FACScalibur flow cytometer
within one hour.
Table 2. mRNA expression of E7-related genes in Hep G2 cell after the silencing of HPV 18 E7 in RT
2 Profiler
TM Human Apoptosis
PCR Array.
Gene names Genbank accession no. Description Folds up- or down-regulation
BAK1 NM_001188 BCL2-antagonist/killer 1 2.48
BAX NM_004324 BCL2-associated X protein 2.07
BCL2 NM_000633 B-cell CLL/lymphoma 2 22.30
BCL2L10 NM_020396 BCL2-like 10 (apoptosis facilitator) 23.05
BIK NM_001197 BCL2-interacting killer (apoptosis-inducing) 2.05
BIRC3 NM_001165 Baculoviral IAP repeat-containing 3 22.14
CARD6 NM_032587 Caspase recruitment domain family, member 6 2.05
CARD8 NM_014959 Caspase recruitment domain family, member 8 2.13
CASP2 NM_032982 Caspase 2, apoptosis-related cysteine peptidase 2.01
CASP8 NM_001228 Caspase 8, apoptosis-related cysteine peptidase 2.03
CASP14 NM_012114 Caspase 14, apoptosis-related cysteine peptidase 3.71
CIDEA NM_001279 Cell death-inducing DFFA-like effector a 2.23
CIDEB NM_014430 Cell death-inducing DFFA-like effector b 2.12
FASLG NM_000639 Fas ligand (TNF superfamily, member 6) 4.00
LTBR NM_002342 Lymphotoxin beta receptor (TNFR superfamily,
member 3)
2.04
NOL3 NM_003946 Nucleolar protein 3 (apoptosis repressor with
CARD domain)
23.92
TNFRSF10A NM_003844 Tumor necrosis factor receptor
superfamily, member 10a
22.06
CD27 NM_001242 CD27 molecule 2.29
TRAF2 NM_021138 TNF receptor-associated factor 2 2.09
TRAF3 NM_003300 TNF receptor-associated factor 3 2.03
TRAF4 NM_004295 TNF receptor-associated factor 4 2.25
In 84 E7-related genes, 21 genes mRNA transcript were altered markedly compared with the negative control. Standards of eligibility: folds up- or down-regulation .2.0
and p,0.05; n=3.
doi:10.1371/journal.pone.0037964.t002
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using real-time PCR human cell cycle and apoptosis
arrays
The real-time PCR microarrays of cell cycle and apoptosis
signaling pathways were purchased from Qiagen (CAT: PAHS-
020 and PAHS-01) and were used according to the manufacturer’s
instructions. The siRNA E7-63 was separately cloned into pGPH1
vector and this was verified through DNA sequencing analysis
performed at Shanghai GenePharma Company. In brief, the real-
time PCR reactions (40 cycles) were performed with sequential
incubations of 10 min at 95uC, 15 seconds at 95uC, and 1 min at
60uC. The fold- change for each gene from experimental group
and control group was expressed as 2
2DDCT. If the fold change was
greater than 2, then the result was reported as a fold up-regulation.
If the fold change was less than 2, then the negative inverse of the
result was reported as a fold down-regulation.
In situ hybridization on tissue microarrays
Tissue samples and microarrays were obtained from National
Engineering Center for BioChip at Shanghai following written
informed consent according to an established protocol approved
by the Ethic Committee of Second Military Medical University.
Datas do not contain any information that may lead to the
identification of the patients. All studies were approved by the
Institutional Ethical Review Board at the Shantou University
Medical College. Tissue microarrays were constructed of 2-mm
cores of patient tissues taken from representative areas of
Hepatocellular carcinoma. Analysis was performed on the 100
independent cases including 28 of grade I, 65 of grade II, 7 of
grade III. We performed in situ hybridization (ISH) using
a Subtype-specific HPV probe on all cases. The ISH screening
was performed using a digoxigenin-labeled HPV probe cocktail
detecting DNA-HPV types 16 and 18 (Triplex International
Figure 6. These photomicrographs show in situ hybridization results for human papillomavirus positive hepatocellular carcinoma.
(A) Hep G2 cells were with the punctate signal pattern of HPV DNA. (B) HeLa cells were served as positive control. (C) Hepatocellular carcinoma was
with diffuse signal pattern of HPV staining. (D) No signal was found in hepatoma carcinoma cells of this HPV- negative specimen.
doi:10.1371/journal.pone.0037964.g006
Table 3. Characteristics of the Hepatocellular Carcinoma Cases With HPV Infection.
Hepatocellular carcinoma case Subtype-specific ISH HPV 16/18 Age Gender Grade
1 + 61 Male I
2 + 42 Male II
3 + 62 Male II
4 + 76 Male II
5 + 45 Male II
6 + 58 Male II
7 + 68 Male II
8 + 61 Male I
9 + 60 Male III
doi:10.1371/journal.pone.0037964.t003
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hematoxylin, dehydrated, and mounted. Positive controls (HeLa
cells) were served with ISH for HPV. Negative controls were
prepared by substituting PBS for the primary antibody. Cases with
HPV signals in the punctate nuclear or diffuse staining of tumor
cells were determined to be positive.
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Table 4. siRNA targeting HPV 18 E7 sites and sequences.
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HPV 18 E7-63 Sense 59- CGGUUGACCUUCUAUGUCATT-39
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HPV 18 E7-74 Sense 59-CUAUGUCACGAGCAAUUAATT -39
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FAM-siRNA
Sense 59-UUCUCCGAACGUGUCACGUTT-39
Anti -sense 59-ACGUGACACGUUCGGAGAATT-
Negative Control siRNA Sense 59- UUCUCCGAACGUGUCACGUTT -39
Anti -sense 59-ACGUGACACGUUCGGAGAATT
-3
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